COMP <GO>
BMRN vs SYRE // DIVIDEND YIELD & FCF PAYOUT SAFETY
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BMRN 5
— SYRE 4
■ METRIC PARITY
LAST: $57.49 (+2.66%) • MKT CAP: $11.13B
dividend-safety
0.00%
LAST: $98.96 (-0.79%) • MKT CAP: $10.33B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. SYRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | SYRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | -20.00% | +26.00 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | -1.64% | +8.15 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 10.80% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 17.60% | -4.70 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 26.00 | -20.43 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 61.9 | -11.90 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.89 | +0.06 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 22.0x | +4.80 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $10.33B | $795.6M | BMRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | SYRE REV | BMRN GROSS % | SYRE GROSS % | BMRN FCF | SYRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $0 | 77.7% | — | $725.0M | -$169.3M |
| FY 2024 | $2.85B | $0 | 79.7% | — | $487.4M | -$157.4M |
| FY 2023 | $2.42B | $886.0K | — | — | $50.4M | -$99.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
SYRE // BETA 0.89